Cencora vs IBM
Side-by-side comparison of AI visibility scores, market position, and capabilities
Conshohocken PA pharmaceutical distribution (NYSE: COR, formerly AmerisourceBergen) at $316B+ revenue; Retina Consultants of America acquisition $4.4B (Jan 2025) expanding into specialty physician care competing with McKesson.
About
Cencora, Inc. (formerly AmerisourceBergen, rebranded August 2023) is a Conshohocken, Pennsylvania-based pharmaceutical distribution and healthcare services company — publicly traded on the New York Stock Exchange (NYSE: COR) as an S&P 500 Health Care component, ranked #10 on the 2024 Fortune 500 and #24 on the Global Fortune 500 — distributing brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and home healthcare supplies to 110,000+ points of care across 11 countries through 46,000+ employees and $316+ billion in annual revenue. Cencora operates as one of the "Big Three" pharmaceutical wholesalers in the United States alongside McKesson and Cardinal Health, collectively supplying approximately 90%+ of the US pharmaceutical supply chain. The company distributes from 26 US pharmaceutical distribution centers and 1,300+ locations across 50+ countries. In January 2025, Cencora completed the acquisition of approximately 85% interest in Retina Consultants of America (RCA) — a leading management services organization for retina specialists — for $4.4 billion, advancing its strategy to expand from pharmaceutical distribution into specialty physician-administered treatments and the high-growth specialty pharmaceutical services market. Founded through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, with predecessor companies tracing to the 1970s, Cencora adopted its current name (meaning "center, core, heart" in multiple languages) in 2023 to signal the brand's evolution beyond commodity distribution.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
About
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
AI Visibility Head-to-Head
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.